{"id":"actemra-eu-licensed","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Gastrointestinal perforation"}]},"_chembl":{"chemblId":"CHEMBL5857501","moleculeType":null,"molecularWeight":"542.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tocilizumab binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signal transduction. This suppresses the production of inflammatory cytokines and acute phase reactants, reducing systemic inflammation in autoimmune and inflammatory conditions.","oneSentence":"Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:05.835Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic sclerosis-associated interstitial lung disease"}]},"trialDetails":[{"nctId":"NCT03606876","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2018-06-13","conditions":"Rheumatoid Arthritis","enrollment":138},{"nctId":"NCT03830203","phase":"PHASE3","title":"Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2018-12-19","conditions":"Rheumatoid Arthritis","enrollment":621},{"nctId":"NCT03282851","phase":"PHASE1","title":"Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2017-11-27","conditions":"Healthy","enrollment":696}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Actemra(EU-licensed)","genericName":"Actemra(EU-licensed)","companyName":"Bio-Thera Solutions","companyId":"bio-thera-solutions","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Actemra (EU-licensed) is used to treat Rheumatoid Arthritis. It is administered via injection, as seen in clinical trials such as NCT03606876, which compared its pharmacokinetics to another version, BAT1806.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}